01—Abstract
Summary
Summary of the 10-Q filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. reported strong revenue growth for the second quarter of 2025, with net sales increasing by 32.8% year-over-year to $668.5 milliona.
This growth was driven by robust performance in both the Connected Devices segment (up 28.6%) and the Software and Services segment (up 38.8%). Despite the top-line growth, the company reported a net loss from operations of $1.0 millionb for the quarter, a decrease from an income of $33.8 million in the prior year, primarily due to a significant increase in operating expenses, particularly in selling, general, and administrative costs driven by higher stock-based compensation and increased headcount. Financially, Axon bolstered its liquidity position significantly, with cash and cash equivalents increasing by $160.7 million to $615.5 million, and total available-for-sale investments growing by $1.1 billion to $1.5 billion, largely following the issuance of $1.75 billion in Senior Notes in March 2025.
The company also experienced a substantial increase in financing cash flows due to these note issuances and ATM equity offerings. While revenue growth is positive, investors should monitor the increasing operating expenses and the impact of stock-based compensation, alongside the company's substantial debt load.
02—Key points
Key Highlights
- Net sales increased by 32.8% to $668.5 million for Q2 2025 compared to Q2 2024.
- Connected Devices segment revenue grew by 28.6%, driven by TASER and Platform Solutions, while Software and Services revenue increased by 38.8% due to user growth and premium feature adoption.
- Operating expenses rose significantly, leading to a loss from operations of $1.0 million in Q2 2025, compared to income from operations of $33.8 million in Q2 2024.
- Stock-based compensation expense saw a substantial increase, impacting gross margin and operating expenses.
- Cash and cash equivalents increased by $160.7 million to $615.5 million, and short-term investments grew by $1.1 billion to $1.5 billion.
- The company issued $1.75 billion in Senior Notes (2030 and 2033), significantly boosting financing activities and liquidity.
- There was a reported material weakness in internal control over financial reporting related to revenue recognition, though efforts to remediate are underway.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Axon Enterprise, Inc. kept $0.05.
- Revenue$668.5M100.0%
- Cost of revenue−$264.8M39.6%
- Gross profit$403.7M60.4%
- Operating costs−$404.8M60.5%
- Operating income−$1.0M0.2%
- Interest, other & tax$37.2M5.6%
- Net income$36.1M5.4%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 5, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $668.54M$503.24M | +32.8% |
| Cost of Revenue | $264.80M$197.08M | +34.4% |
| Gross Profit | $403.74M$306.16M | +31.9% |
| R&D Expenses | $162.57M$101.43M | +60.3% |
| SG&A Expenses | $242.21M$170.96M | +41.7% |
| Operating Expenses | $404.78M$272.40M | +48.6% |
| Operating Income | -$1.04M$33.76M | −103.1% |
| Net Income | $36.12M$41.47M | −12.9% |
| EPS (Basic) | $0.46$0.55 | −16.4% |
| EPS (Diluted) | $0.44$0.53 | −17.0% |
| Shares Outstanding (Basic) | 78.00M75.51M | +3.3% |
| Shares Outstanding (Diluted) | 82.06M77.55M | +5.8% |
05—Questions
Frequently Asked Questions
What was the primary driver behind the company's operational loss in the second quarter of 2025?
The company reported a loss from operations of $1.0 million for the second quarter of 2025, a decrease from an income of $33.8 million in the prior year. This was primarily driven by a significant increase in operating expenses, particularly selling, general, and administrative costs, which rose by 41.7% year-over-year. This increase was largely attributed to higher stock-based compensation expenses related to new equity awards and increased headcount to support business growth.
How did the issuance of Senior Notes impact the company's financial position?
In March 2025, Axon issued $1.0 billion in Senior Notes due 2030 and $750.0 million in Senior Notes due 2033, totaling $1.75 billion in aggregate principal. This significantly boosted the company's liquidity, with total cash and available-for-sale investments increasing by approximately $1.3 billion from December 31, 2024, to $2.09 billion as of June 30, 2025. It also increased the company's long-term debt to $1.73 billion.
What is the status of the material weakness in internal control over financial reporting?
Axon disclosed a material weakness in its internal control over financial reporting related to revenue recognition, as previously reported. While remediation efforts are ongoing, the company states that the material weakness cannot be considered remediated until controls have been effectively implemented and operated for a sufficient period. However, a previously identified material weakness related to the classification of the 2027 Notes between current and long-term liabilities has been remediated as of June 30, 2025.
How did the company's investments perform in the period?
The company saw a substantial increase in its available-for-sale investments, growing by $1.1 billion to $1.5 billion as of June 30, 2025. This growth was primarily a result of investment activity following the issuance of Senior Notes. The company also reported significant gains related to strategic investments, including a $166.0 million gain (net of realized and unrealized adjustments) for the first six months of 2025, largely driven by an observable price change and subsequent sale of an existing strategic investee.
06—Continue